MedEngine has been granted a partnership in the European Network of Centres for Pharmacoepidemiology & Pharmacovigilance (ENCePP), an initiative that brings together expertise and resources in pharmacoepidemiology and pharmacovigilance across Europe. ENCePP aims to facilitate the conduct of high-quality, multi-center, independent post-authorization studies (PAS) with a focus on observational research. ENCePP is coordinated by the European Medicines Agency.
”At MedEngine, we have put a lot of effort in building state-of-the-art processes for real-world evidence research, ranging from highest quality of documentation and privacy practices to top-notch analytics pipeline.”
“ENCePP partnership is an important step for us to be able to conduct even the most demanding RWE-projects, which may range from post-authorization safety studies to clinical trials involving registry-based control arms,” says Tero Ylisaukko-oja, CEO of MedEngine.
Read more about ENCePP here.
